Veracyte Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
Veracyte Stock Forecast and Price Target
The average price target for Veracyte's stock lately set by several renowned analysts is $32.50, which would result in a potential upside of approximately 60.97% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of $37.00 and a low estimate of $21.00. Even if you are not interested in VCYT stock, you should still be aware of its competitors.
60.97% Upside
Veracyte Fair Value Forecast for 2023 - 2025 - 2030
Veracyte's Price has grown In the last four years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $21.69 – an increase of 100.00%. For the next seven years, experts predict that Veracyte's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF88.87 | Buy/Sell | CHF105.00 | 21.10% |
| HOLX Stock Forecast | Hologic | Outperform |
8
|
$75.91 | Buy/Sell | $81.06 | 10.66% |
| LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$200.25 | Buy/Sell | $241.28 | 20.35% |
| DGX Stock Forecast | Quest Diagnostics | Outperform |
10
|
$136.34 | Buy/Sell | $141.17 | 6.35% |
| ERF Stock Forecast | Eurofins Scientific | Hold |
18
|
56.50€ | Buy/Sell | 0.00€ | 6.19% |
Veracyte Revenue Forecast for 2023 - 2025 - 2030
Veracyte's Revenue has grown In the last three years, rising from $117.48M to $361.05M – a growth of 207.33%. In the next year, analysts believe that Revenue will reach $391.14M – an increase of 8.33%. For the next seven years, experts predict that Veracyte's Revenue will grow at a rate of 9.68%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NTRA Stock Forecast | Natera | Outperform |
7
|
$93.72 | Buy/Sell | $74.41 | 9.90% |
| EXAS Stock Forecast | Exact Sciences | Buy |
8
|
$60.54 | Buy/Sell | $90.32 | 46.37% |
| QGEN Stock Forecast | QIAGEN N.V. | Outperform |
15
|
$42.68 | Buy/Sell | $0.00 | 17.15% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SHL Stock Forecast | Sonic Healthcare | Hold |
18
|
$25.94 | Buy/Sell | $34.12 | 19.51% |
| GH Stock Forecast | Guardant Health | Buy |
6
|
$18.58 | Buy/Sell | $43.00 | 136.81% |
| NEO Stock Forecast | NeoGenomics | Outperform |
8
|
$14.72 | Buy/Sell | $20.09 | 29.08% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MYGN Stock Forecast | Myriad Genetics | Hold |
6
|
$19.22 | Buy/Sell | $22.08 | 30.07% |
| OPK Stock Forecast | OPKO Health | Outperform |
8
|
$1.01 | Buy/Sell | $6.70 | 296.04% |
| VNET Stock Forecast | VNET Group | Outperform |
11
|
$1.91 | Buy/Sell | $33.17 | 1283.25% |
Veracyte EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Veracyte's EBITDA has grown, moving from $-24.85M to $9.74M – an increase of 139.20%. For the next year, 2 analysts project Veracyte's EBITDA to drop by 26.18%, reaching $7.19M. Looking ahead to seven years, experts forecast that EBITDA will grow by 429.87%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CDNA Stock Forecast | CareDx, Inc | Outperform |
9
|
$9.27 | Buy/Sell | $11.80 | 40.24% |
| CRDF Stock Forecast | Cardiff Oncology | Buy |
10
|
$4.23 | Buy/Sell | $8.37 | 105.20% |
| PEB Stock Forecast | Pacific Edge | Hold |
11
|
$0.10 | Buy/Sell | $0.14 | 40.00% |
Veracyte EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Veracyte's EBIT has fallen from $-32.80M to $-17.45M – a 46.80% decrease. Analysts predict that Veracyte's EBIT will increase in the upcoming year, reaching $-22.15M. This would represent an increase of 26.93%. Over the next seven years, experts predict that Veracyte's EBIT will grow at a rate of 6.72%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DMTK Stock Forecast | DermTech | Outperform |
7
|
$0.62 | Buy/Sell | $3.60 | 141.94% |
| AXDX Stock Forecast | Accelerate Diagnostics | Buy |
8
|
$0.94 | Buy/Sell | $5.00 | -100.00% |
| OCX Stock Forecast | OncoCyte | Outperform |
6
|
$2.55 | Buy/Sell | $3.90 | 61.96% |
Veracyte EPS Price Prediction Forecast for 2023 - 2025 - 2030
Veracyte's EPS has grown In the last four years, rising from $-0.66 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $-0.11 – an increase of 100.00%. For the next seven years, experts predict that Veracyte's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NSTG Stock Forecast | NanoString Technologies | - |
7
|
$0.19 | Buy/Sell | $5.02 | -100.00% |
| IDXG Stock Forecast | Interpace Biosciences | - |
0
|
$1.06 | Buy/Sell | $11.00 | -100.00% |
| NVTA Stock Forecast | Invitae | - |
4
|
$0.00 | Buy/Sell | $0.71 | 0.00% |
.jpg)